Literature DB >> 12966522

Rett syndrome in a 47,XXX patient with a de novo MECP2 mutation.

Sara Hammer1, Naghmeh Dorrani, Jaana Hartiala, Stuart Stein, N Carolyn Schanen.   

Abstract

Rett syndrome is caused by mutation in MECP2, a gene located on Xq28 and subject to X-inactivation. MECP2 encodes methyl CpG-binding protein 2, a widely expressed transcriptional repressor of methylated DNA. Mutations in MECP2 are primarily de novo events in the male germ line and thus lead to an excess of affected females. Here we report the identification of a unique 47,XXX girl with relatively mild atypical Rett syndrome leading initially to a diagnosis of infantile autism with regression. Mutation analysis of the MECP2 gene identified a de novo MECP2 mutation, L100V. Examination of a panel of X-linked microsatellite markers indicated that her supernumerary X chromosome is maternally derived. X-inactivation patterns were determined by analysis of methylation of the androgen receptor locus, and indicated preferential inactivation of her paternal allele. The parental origin of her MECP2 mutation could not be determined because she was uninformative for intronic polymorphisms flanking her mutation. This is the first reported case of sex chromosome trisomy and MECP2 mutation in a female, and it illustrates the importance of allele dosage on the severity of Rett syndrome phenotype. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12966522     DOI: 10.1002/ajmg.a.20320

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  2 in total

1.  X-chromosome inactivation patterns are unbalanced and affect the phenotypic outcome in a mouse model of rett syndrome.

Authors:  Juan I Young; Huda Y Zoghbi
Journal:  Am J Hum Genet       Date:  2004-02-17       Impact factor: 11.025

2.  Atypical Rett syndrome in a girl with mosaic triple X and MECP2 variant.

Authors:  Satoru Takahashi; Ryo Takeguchi; Mami Kuroda; Ryosuke Tanaka
Journal:  Mol Genet Genomic Med       Date:  2020-01-13       Impact factor: 2.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.